SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS
Safety profiles of the novel oral anticoagulants (NOAC) (rivaroxaban, apixaban, edoxaban, dabigatran) are better than that of warfarin. However, the risk (including lifethreatening) of bleeding is no less than 2.3-3.1% per year. Three specific antidotes to NOAC are currently in different phases...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
«REMEDIUM GROUP» Ltd.,
2016-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |